Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Lopinavir prices in Germany, the highest-cost reporting region, corrected 5.0% in Q2 2026, slipping from USD 152.4/KG in Q1 to USD 144.8/KG as synthesis intermediate cost softening and post-spring HIV antiretroviral programme formulation procurement moderation reversed the sustained Q3 2025 through Q1 2026 firming trend. Globally, the average eased from USD 105.91/KG in Q1 to USD 100.61/KG in Q2, a 5.0% decline. For H2 2026, a global average of USD 98.50-108.50/KG is expected, with stabilisation as synthesis costs normalise and steady HIV combination antiretroviral therapy and pharmacokinetic booster demand supports the market across all major regions.
Lopinavir is a peptidomimetic HIV-1 protease inhibitor produced by multi-step asymmetric synthesis from valine-derived chiral building blocks and methylated pyrrolidine ring intermediates, assembled through amide bond formation, reductive amination, and Boc protecting group manipulation steps to yield the complex urea-containing backbone structure with the required stereochemical configuration at all chiral centres. The compound binds with high affinity to the HIV-1 protease active site, blocking cleavage of gag and pol polyprotein precursors and preventing the formation of mature, infectious viral particles. Lopinavir is exclusively formulated in a fixed-dose oral combination with low-dose ritonavir as a pharmacokinetic booster, which inhibits CYP3A4-mediated lopinavir metabolism and sustains therapeutically effective plasma concentrations throughout the dosing interval. The lopinavir plus ritonavir fixed-dose combination tablet is a key second-line antiretroviral option in global HIV treatment programmes, particularly valued in resource-limited settings for its heat-stable formulation. Paediatric oral solution and granule formulations extend reach to younger patients. Synthesis intermediate costs, HIV programme volumes, and regional API capacity all feed into the price.
The balance of supply and demand for lopinavir through H2 2026 leans toward stabilisation following the Q2 correction. Synthesis intermediate costs are normalising after the Q1 2026 peak. HIV antiretroviral programme procurement, fixed-dose combination tablet restocking, and paediatric formulation demand provide consistent procurement support.
The main upside risk is a renewed synthesis intermediate cost spike from precursor supply disruption alongside accelerating HIV programme scale-up. The main downside risk is continued Chinese and Indian generic API surplus maintaining price pressure below forecast.
| Region | Price Forecast (USD/KG) | Key Driver |
| Global Average | 98.50 - 108.50 | Synthesis cost normalisation and HIV ARV combination demand |
| United States | 105.20 - 115.20 | Steady HIV programme combination therapy demand holds firm |
| China | 74.60 - 84.60 | Domestic API capacity keeps it the most affordable |
| Germany | 138.40 - 148.40 | High synthesis and energy costs keep it the most expensive |
| India | 100.90 - 110.90 | Growing HIV export and domestic programme demand holds a firm middle |
US Lopinavir prices averaged USD 118.1/KG in Q2 2026, down 5.0% from USD 124.3/KG in Q1 2026. Synthesis intermediate cost softening and post-spring HIV antiretroviral programme procurement moderation eased the market from the Q1 firming peak.
Why did the price of Lopinavir change in Q2 2026 in the United States?
Synthesis intermediate cost softening reduced the peptidomimetic API production floor. Post-spring HIV programme combination tablet procurement moderation reduced buying urgency. Generic competition and adequate API supply maintained price normalisation near USD 118.1/KG.
Chinese Lopinavir prices averaged USD 82.1/KG in Q2 2026, down 5.0% from USD 86.4/KG in Q1 2026, the lowest among the tracked markets. Soft domestic synthesis intermediate costs and post-spring HIV programme procurement moderation eased the market from the Q1 peak.
Why did the price of Lopinavir change in Q2 2026 in China?
Soft domestic synthesis intermediate costs reduced the API production floor. Post-spring HIV programme combination export and domestic procurement moderation reduced buying urgency. Domestic API capacity maintained China as the most affordable source near USD 82.1/KG.
German Lopinavir prices averaged USD 144.8/KG in Q2 2026, down 5.0% from USD 152.4/KG in Q1 2026, the highest among the tracked markets. Softening synthesis intermediate and energy costs and post-spring HIV programme procurement moderation eased the European market from the Q1 firming peak.
Why did the price of Lopinavir change in Q2 2026 in Germany?
Softening synthesis intermediate and energy costs eased the European peptidomimetic API production floor. Post-spring HIV antiretroviral programme combination tablet procurement moderation reduced buying urgency. The market corrected to USD 144.8/KG from the Q1 2026 firming peak.
Indian Lopinavir prices averaged USD 111.4/KG in Q2 2026, down 5.0% from USD 117.3/KG in Q1 2026. Soft synthesis import costs and post-spring HIV programme procurement moderation eased the market from the Q1 peak.
Why did the price of Lopinavir change in Q2 2026 in India?
Soft synthesis intermediate import costs reduced the production floor. Post-spring HIV programme combination tablet procurement moderation eased buying urgency. Export and domestic price normalisation held the market near USD 111.4/KG after the Q1 firming peak.
US Lopinavir prices averaged USD 124.3/KG in Q1 2026, up 4.0% from Q4 2025. Firmer synthesis intermediate costs and winter HIV programme combination tablet procurement held the market at the Q1 firming peak.
Why did the price of Lopinavir change in Q1 2026 in the United States?
Firmer peptidomimetic synthesis intermediate costs raised the API production floor. HIV programme combination tablet and paediatric formulation procurement maintained buying at elevated levels. The market held at USD 124.3/KG before the Q2 correction.
Chinese prices averaged USD 86.4/KG in Q1 2026, up 4.0% from Q4 2025. Firmer domestic synthesis costs and post-Lunar New Year HIV programme export procurement held the market at the Q1 peak.
Why did the price of Lopinavir change in Q1 2026 in China?
Firmer domestic synthesis intermediate costs raised the production floor. Post-Lunar New Year HIV programme export procurement maintained elevated buying. The market reached USD 86.4/KG before the Q2 synthesis cost softening correction.
German prices averaged USD 152.4/KG in Q1 2026, up 4.0% from Q4 2025. Firmer synthesis intermediate and energy costs and HIV programme combination procurement held the European market at the Q1 peak.
Why did the price of Lopinavir change in Q1 2026 in Germany?
Firmer synthesis intermediate and energy costs raised the European production floor. HIV antiretroviral programme combination tablet procurement maintained elevated buying. The market held at USD 152.4/KG before the Q2 softening.
Indian prices averaged USD 117.3/KG in Q1 2026, up 4.0% from Q4 2025. Firmer synthesis import costs and HIV programme export and domestic procurement held the market at the Q1 firming peak.
Why did the price of Lopinavir change in Q1 2026 in India?
Firmer synthesis import costs raised the production floor. HIV programme combination and paediatric export procurement maintained elevated buying. The market held at USD 117.3/KG before the Q2 correction.
Global Lopinavir prices rose steadily through Q3 2025, Q4 2025, and Q1 2026 on firming synthesis intermediate costs and consistent HIV programme procurement, before correcting in Q2 2026. The average climbed from USD 96.0/KG in Q2 2025 to USD 97.92/KG in Q3, USD 101.84/KG in Q4, and USD 105.91/KG in Q1 2026, then corrected to USD 100.61/KG in Q2 2026, a net gain of about 4.8% over the window. Peptidomimetic synthesis intermediate cost cycles and HIV programme procurement drove the rising trajectory before the Q2 correction.
| Quarter | Price (USD/KG) | QoQ Change | Direction |
| Q2 2026 | 100.61 | -5.0% | ↓ Falling |
| Q1 2026 | 105.91 | +4.0% | ↑ Rising |
| Q4 2025 | 101.84 | +4.0% | ↑ Rising |
| Q3 2025 | 97.92 | +2.0% | ↑ Rising |
| Q2 2025 | 96.0 | - | - Stable |
| Q3 2026 | In Progress | - | - In Progress |
Lopinavir prices firmed steadily through 2025 on growing HIV programme procurement and synthesis intermediate cost support. The global average opened near USD 93.5/KG in Q1 2025 and closed at USD 101.84/KG in Q4, a full-year gain of about 8.9%. Firming peptidomimetic synthesis intermediate costs and consistent HIV combination antiretroviral programme procurement drove the upward trajectory throughout the year.
US prices firmed from about USD 110.5/KG in Q1 2025 to USD 119.5/KG by Q4, a gain of 8.1%. Consistent HIV programme combination therapy and paediatric formulation demand supported the upward trend.
Chinese prices firmed from roughly USD 77.2/KG in Q1 2025 to USD 83.1/KG by Q4, a gain of 7.6%. Growing HIV export programme and domestic combination therapy demand drove the firming.
German prices firmed from about USD 135.8/KG in Q1 2025 to USD 146.5/KG by Q4, a gain of 7.9%. Consistent HIV programme combination therapy demand and firm synthesis costs supported the market.
Indian prices firmed from roughly USD 104.5/KG in Q1 2025 to USD 112.8/KG by Q4, a gain of 7.9%. Growing HIV export programme and domestic combination therapy demand drove consistent firming.
Expert Market Research: Your Source for Real-Time Lopinavir Price Intelligence
Expert Market Research tracks Lopinavir prices continuously across every major producing and consuming region. The team traces causation through peptidomimetic synthesis intermediate economics, HIV antiretroviral programme procurement cycles, and regional API production capacity. Contact Expert Market Research today for Lopinavir pricing data, bespoke market analysis, and strategic procurement advisory.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Fixed-dose combination with ritonavir as second-line antiretroviral therapy in global HIV-1 treatment programmes takes the largest share, particularly in resource-limited settings where heat-stable tablet formulations support programmatic delivery. Paediatric oral solution and granule formulations for HIV-infected children and adolescents also consume significant volumes through international health programme procurement globally.
The Q2 2026 average was USD 118.1/KG in the United States, USD 82.1/KG in China, USD 144.8/KG in Germany, and USD 111.4/KG in India. Germany remains the highest-priced market after the Q2 correction.
The global average rose to a peak of USD 105.91/KG in Q1 2026 before correcting to USD 100.61/KG in Q2, a 5.0% quarterly decline. Sustained synthesis intermediate cost firming through Q1 and post-spring HIV programme procurement moderation drove the rise-and-correct pattern.
Peptidomimetic synthesis intermediate cost softening reduced the API production floor. Post-spring HIV antiretroviral programme combination tablet procurement moderation reduced buying urgency from the Q1 seasonal firming peak, allowing the Q2 price correction.
The global average is expected in the USD 98.50 to 108.50/KG range for H2 2026, with stabilisation as synthesis intermediate costs normalise and HIV combination antiretroviral therapy programme demand resumes at steady levels globally.
Germany sits highest on synthesis and energy costs, the United States and India hold a firm middle on HIV programme demand, and China prices lowest on domestic API production capacity.
This report is updated monthly. For real-time pricing intelligence, contact the Expert Market Research team directly.
Prices respond mainly to peptidomimetic synthesis intermediate costs, HIV antiretroviral programme procurement scale, and PEPFAR and global health fund procurement decisions. HIV programme funding announcements and synthesis precursor pricing are key signals.
China and India hold the largest lopinavir API synthesis capacity. Any synthesis intermediate cost shift ripples across markets within one to two quarters.
Buyers can use quarterly trends and forecasts to time HIV combination tablet contracts around synthesis cost cycles, build cover when intermediate signals tighten, and monitor PEPFAR and global health fund procurement signals as primary demand inputs.
One Year Subscription
One Year Subscription
USD 799
USD 699
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.